Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Apr 12, 2026, 15:54Ralf Illing: Proud to Contribute My Patient Voice to OCEANIC-STROKE Research
-
Apr 12, 2026, 15:38Hugo Antonio Romo Rubio: ASH ISTH 2026 Guidelines on Prophylactic Anticoagulation In Pediatrics
-
Apr 12, 2026, 15:26Melissa Lewellyn: The DVT and PE Awareness Resolution from NBCA Is Now Live
-
Apr 12, 2026, 14:58Akram Shibani: HI-PEITHO Trial Reminds Us Why Composite Endpoints Deserve Careful Scrutiny
-
Apr 12, 2026, 14:493 Days, 14 Leaders, 1 Mission at The 13th EHC Youth Leadership Workshop
-
Apr 12, 2026, 14:27Moustafa Abdou: Paroxysmal Nocturnal Hemoglobinuria From a Rare Disease to a Treatable Condition
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams